Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Angels Are Going Where VCs Fear To Tread

This article was originally published in Start Up

Executive Summary

Many VCs have lost interest in early-stage investing, but angels - individuals who invest their own money alone or in groups - are stepping up to fill the gap. Angels are an especially good fit for for biotech start-ups that don't want to cede control of their companies to VCs too early, if at all. In addition to bringing valuable cash, angels put less pressure on start-ups to achieve an exit within a given time frame than traditional venture investors, and are more willing to accept buyers that may not be the highest bidders but will nevertheless be good stewards for their assets. For their part, companies looking to angels must understand the goals of their potential backers, since these financiers are often motivated by philanthropy and personal interest in a disease.
Advertisement

Related Content

Taking Wing With Biotech Angel Investors
For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon
Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble
Karyopharm Scores $48M Series B To Advance Early Cancer Compounds
Angels Share In Biotech Rewards, But Rarely In Drug Discovery
Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model
Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model,
Ascletis Raises Mammoth $100 Million To Deploy Its US-China Hybrid Model
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
Reacting to the Crisis: Biotech Venture Capital's Plan B

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel